Recent Progression on Phytochemicals and Pharmacological Properties of the Filamentous Cyanobacterium Lyngbya Sp

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2023 Apr 27

PMID 37103519

Authors

Surendra Swain

Shuvasree Bej

Ajit Kumar Bishoyi

Chinmayee Priyadarsani Mandhata

Chita Ranjan Sahoo

Rabindra Nath Padhy

Affiliations

Soon will be listed here.

Abstract

The distribution and phytochemistry of the non-nitrogen fixing, filamentous cyanobacterium (blue-green alga) Lyngbya sp., and the inherent antimicrobial and anticancer activities of its phycochemicals as well as of the biosynthesized nanoparticles as their pharmaceutical potencies are considered. Several phycocompounds of curio, apramide, apratoxin, benderamide, cocosamides, deoxymajusculamide, flavonoids, lagunamides, lipids, proteins, amino acids, lyngbyabellin, lyngbyastatin, majusculamide, peptides, etc. were isolated from Lyngbya sp., which had a lot of potential pharmaceutical activities; those compounds had antibacterial, antiviral, antifungal, anticancer, antioxidant, anti-inflammatory, ultraviolet protectant, and other activities. Particularly, several Lyngbya phycocompounds had potent antimicrobial potencies, seen through in vitro controlling of several frequently encountered multidrug-resistant (MDR) clinically belligerent strains of pathogenic bacteria isolated from clinical samples. The aqueous extracts of Lyngbya sp. were used for the synthesis of silver and copper oxide nanoparticles, which were used in pharmacological trials too. The nanoparticles biosynthesized with Lyngbya sp. had several uses such as biofuel, agro-based applications, in cosmetics, and industrial uses as biopolymers, and being potent antimicrobial and anticancer agents and in drug-delivery too, as medical applications. It could be concluded that the Lyngbya phycochemicals and the biosynthesized nanoparticles have future uses as antimicrobial namely as bacterial and fungal and anti-cancer agents, with promising medical and industrial uses.

Citing Articles

Assessment and identification of bioactive metabolites from terrestrial Lyngbya spp. responsible for antioxidant, antifungal, and anticancer activities.

Verma S, Suman P, Mandal S, Kumar R, Sahana N, Siddiqui N Braz J Microbiol. 2023; 54(4):2671-2687.

PMID: 37688688 PMC: 10689636. DOI: 10.1007/s42770-023-01111-1.

References

Al-Awadhi F, Ratnayake R, Paul V, Luesch H . Tasiamide F, a potent inhibitor of cathepsins D and E from a marine cyanobacterium. Bioorg Med Chem. 2016; 24(15):3276-82. PMC: 4957937. DOI: 10.1016/j.bmc.2016.04.062. View

Ashaolu T, Samborska K, Lee C, Tomas M, Capanoglu E, Tarhan O . Phycocyanin, a super functional ingredient from algae; properties, purification characterization, and applications. Int J Biol Macromol. 2021; 193(Pt B):2320-2331. DOI: 10.1016/j.ijbiomac.2021.11.064. View

Blunt J, Copp B, Keyzers R, Munro M, Prinsep M . Marine natural products. Nat Prod Rep. 2017; 34(3):235-294. DOI: 10.1039/c6np00124f. View

Chandra R, Das P, Vishal G, Nagra S . Factors affecting the induction of UV protectant and lipid productivity in Lyngbya for sequential biorefinery product recovery. Bioresour Technol. 2019; 278:303-310. DOI: 10.1016/j.biortech.2019.01.084. View

Chen J, Fu X, Zhou L, Zhang J, Qi X, Cao X . A convergent route for the total synthesis of malyngamides O, P, Q, and R. J Org Chem. 2009; 74(11):4149-57. DOI: 10.1021/jo9003103. View

Devi A, Prasanth S, Murugesh E, Haridas K, Sabu A, Haridas M . A Novel, Poly(Ethyl Ethylene Ether) Inhibitor to Trypsin from Marine Cyanobacteria, Lyngbya confervoides. Appl Biochem Biotechnol. 2015; 178(5):891-9. DOI: 10.1007/s12010-015-1916-4. View

Gunasekera S, Owle C, Montaser R, Luesch H, Paul V . Malyngamide 3 and cocosamides A and B from the marine cyanobacterium Lyngbya majuscula from Cocos Lagoon, Guam. J Nat Prod. 2011; 74(4):871-6. PMC: 3081898. DOI: 10.1021/np1008015. View

Gutierrez M, Suyama T, Engene N, Wingerd J, Matainaho T, Gerwick W . Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria Lyngbya majuscula and Lyngbya sordida. J Nat Prod. 2008; 71(6):1099-103. DOI: 10.1021/np800121a. View

Gutierrez M, Tidgewell K, Capson T, Engene N, Almanza A, Schemies J . Malyngolide dimer, a bioactive symmetric cyclodepside from the panamanian marine cyanobacterium Lyngbya majuscula. J Nat Prod. 2010; 73(4):709-11. PMC: 2859090. DOI: 10.1021/np9005184. View

10.

Han B, Goeger D, Maier C, Gerwick W . The wewakpeptins, cyclic depsipeptides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Org Chem. 2005; 70(8):3133-9. DOI: 10.1021/jo0478858. View

11.

Han B, Reinscheid U, Gerwick W, Gross H . The structure elucidation of isomalyngamide K from the marine cyanobacterium Lyngbya majuscula by experimental and DFT computational methods. J Mol Struct. 2011; 989(1-3):109-113. PMC: 3066435. DOI: 10.1016/j.molstruc.2011.01.012. View

12.

Harrigan G, Yoshida W, Moore R, Nagle D, Park P, Biggs J . Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. J Nat Prod. 1998; 61(10):1221-5. DOI: 10.1021/np9801211. View

13.

Iwasaki A, Ohno O, Sumimoto S, Ogawa H, Nguyen K, Suenaga K . Jahanyne, an apoptosis-inducing lipopeptide from the marine cyanobacterium Lyngbya sp. Org Lett. 2015; 17(3):652-5. DOI: 10.1021/ol5036722. View

14.

Janani B, Al Farraj D, Raju L, Elshikh M, Alkubaisi N, Thomas A . Cytotoxicological evaluation of copper oxide nanoparticles on green algae, bacteria and crustacean systems. J Environ Health Sci Eng. 2020; 18(2):1465-1472. PMC: 7721846. DOI: 10.1007/s40201-020-00561-1. View

15.

Knights K, Mangoni A, Miners J . Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol. 2011; 3(6):769-76. DOI: 10.1586/ecp.10.120. View

16.

Kumar M, Tripathi M, Srivastava A, Gour J, Singh R, Tilak R . Cyanobacteria, Lyngbya aestuarii and Aphanothece bullosa as antifungal and antileishmanial drug resources. Asian Pac J Trop Biomed. 2013; 3(6):458-63. PMC: 3644573. DOI: 10.1016/S2221-1691(13)60096-9. View

17.

Kumar M, Singh P, Tripathi J, Srivastava A, Tripathi M, Ravi A . Identification and structure elucidation of antimicrobial compounds from Lyngbya aestuarii and Aphanothece bullosa. Cell Mol Biol (Noisy-le-grand). 2014; 60(5):82-9. View

18.

Levert A, Alvarino R, Bornancin L, Abou Mansour E, Burja A, Geneviere A . Structures and Activities of Tiahuramides A-C, Cyclic Depsipeptides from a Tahitian Collection of the Marine Cyanobacterium Lyngbya majuscula. J Nat Prod. 2018; 81(6):1301-1310. DOI: 10.1021/acs.jnatprod.7b00751. View

19.

Liu L, Rein K . New peptides isolated from Lyngbya species: a review. Mar Drugs. 2010; 8(6):1817-37. PMC: 2901827. DOI: 10.3390/md8061817. View

20.

Lopez J, Al-Lihaibi S, Alarif W, Abdel-Lateff A, Nogata Y, Washio K . Wewakazole B, a Cytotoxic Cyanobactin from the Cyanobacterium Moorea producens Collected in the Red Sea. J Nat Prod. 2016; 79(4):1213-8. DOI: 10.1021/acs.jnatprod.6b00051. View